Cabozantinib significantly improves overall survival in previously treated patients with advanced renal cell carcinoma (RCC) compared to everolimus, with consistent results after long-term follow-up.
Results from a second interim analysis of the phase 3 METEOR trial have been published in the British Journal of Cancer, showing cabozantinib significantly improved overall survival compared with everolimus in patients with advanced RCC after prior treatment with a vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor (TKI).
In the first interim analysis from the phase 3 METEOR trial, cabozantinib significantly improved progression-free survival, overall survival, and objective response rate compared with everolimus in previously treated patients with advanced RCC.
In the trial, 658 patients with advanced RCC who had received at least one prior VEGF receptor TKI were randomised to receive either cabozantinib or everolimus. The patients were followed to collect overall survival data.
Median overall survival was 21.4 months with cabozantinib and 17.1 months with everolimus. Safety profiles of cabozantinib and everolimus were consistent with those reported previously.